Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors

Patricia M. LoRusso, Roy S. Herbst, Danny Rischin, Malcolm Ranson, Hilary Calvert, Eric Raymond, Dirk Kieback, Stan Kaye, Luca Gianni, Adrian Harris, Thomas Bjork, Anne Marie Maddox, Mace L. Rothenberg, Eric J. Small, Eric H. Rubin, Andrea Feyereislova, Anne Heyes, Steven D. Averbuch, Judith Ochs, José Baselga

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors'. Together they form a unique fingerprint.

Medicine & Life Sciences